574,455 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Purchased by Renaissance Technologies LLC

Renaissance Technologies LLC bought a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 574,455 shares of the company's stock, valued at approximately $2,080,000. Renaissance Technologies LLC owned approximately 0.68% of Atyr PHARMA at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Alterna Wealth Management Inc. purchased a new position in shares of Atyr PHARMA during the fourth quarter worth about $36,000. Victory Capital Management Inc. purchased a new position in Atyr PHARMA during the 4th quarter worth approximately $37,000. Raymond James Financial Inc. acquired a new position in Atyr PHARMA during the fourth quarter worth approximately $39,000. ExodusPoint Capital Management LP purchased a new stake in Atyr PHARMA in the fourth quarter valued at approximately $61,000. Finally, Farther Finance Advisors LLC purchased a new position in shares of Atyr PHARMA during the fourth quarter worth approximately $88,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Leerink Partners started coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price target for the company. Cantor Fitzgerald initiated coverage on Atyr PHARMA in a research report on Monday, January 6th. They issued an "overweight" rating on the stock. Leerink Partnrs raised Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $35.00 price target on shares of Atyr PHARMA in a report on Friday, March 14th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $18.60.

Atyr PHARMA Price Performance

Atyr PHARMA stock traded down $0.08 during midday trading on Monday, reaching $3.27. The company's stock had a trading volume of 1,565,103 shares, compared to its average volume of 902,510. The firm has a market capitalization of $290.57 million, a PE ratio of -3.48 and a beta of 0.95. Atyr PHARMA INC has a fifty-two week low of $1.42 and a fifty-two week high of $4.66. The stock's 50 day simple moving average is $3.35 and its 200 day simple moving average is $3.38. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, equities research analysts forecast that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.